Another Phase II randomized, double‐blind, placebo‐controlled trial (NRP101 202) validated target engagement through cerebrospinal fluid biomarkers of PKC activation, and further demonstrated that bryostatin‐1 improves cognitive function via PKCε activation [362], with especially notable effects in late‐stage AD patients not receiving memantine and an overall manageable safety profile [363]. Here, PRKCE is linked to Alzheimer disease.